Table 2.

Differential lncRNA expression and fold differences between breast cancer tumors and benign tissues (Validation experiment)

lncRNA	FD (Ct $⩽$ 40)	95% CI, low	95% CI, high	$P$
Downregulated expression
PTENP1	$-$8.06	$-$12.38	$-$5.25	0.00000001
MAGI2-AS3	$-$5.89	$-$10.02	$-$3.46	0.00000020
MEG3	$-$3.83	$-$5.40	$-$2.72	0.00000014
GNG12-AS1	$-$3.35	$-$4.95	$-$2.27	0.00000141
Upregulated expression
UCA1	2.16	1.32	3.54	0.00740687
NRSN2-AS1	1.73	1.29	2.31	0.00049781
lncRNA	FD (Ct 35)	95% CI, low	95% CI, high	$P$
Downregulated expression
PTENP1	$-$8.13	$-$12.44	$-$5.31	0.00000001
MAGI2-AS3	$-$5.89	$-$10.02	$-$3.46	0.00000020
MEG3	$-$3.83	$-$5.40	$-$2.72	0.00000014
GNG12-AS1	$-$3.35	$-$4.95	$-$2.27	0.00000141
Upregulated expression
NRSN2-AS1	1.71	1.28	2.29	0.00060548
UCA1	1.55	1.02	2.34	0.04113247

Notes: FD, fold difference; CI, confidential interval. Three endogenous controls (18S rRNA, GAPDH and actin beta) were used for data normalizations. Two cut-offs of expression level, i.e. Ct 35 and Ct $⩽$ 40 were applied.